Literature DB >> 11579927

Adjustment of prognostic effects in prevalent case-control studies on genotype.

N Hamajima1, K Matsuo, H Yuasa.   

Abstract

Since genotypes are unchangeable, adjustment of prognostic effects in prevalent case-control studies may produce an unbiased estimate of odds ratio (OR) for disease occurrence. In this paper, the prognostic effects on OR is demonstrated, then three approaches to examine and/or adjust the OR are presented. The demonstration shows that the prognostic effects are larger in diseases with poor prognosis than in those with better prognosis. Genotypes increasing disease risk and fatality rate are underestimated, while those increasing the risk and improving prognosis are overestimated. The simplest approach to examine the OR derived from prevalent case-control studies is to conduct stratified analysis according to the interval between diagnosis and study enrollment. When the stratified analysis finds no substantial difference in the estimate, the OR reflects mainly the relative risk for disease occurrence. The proportion of genotype among putative cases at diagnosis can be estimated from prevalent cases by a logistic model, producing the OR adjusted for the interval from diagnosis. An incomplete-data case-control design is also applicable to adjust the prognostic effects. An actual prevalent case-control study on breast cancer is used to demonstrate the three approaches. They are useful to compensate the disadvantage of prevalent case-control studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579927     DOI: 10.2188/jea.11.204

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  2 in total

1.  L-myc genotype is associated with different susceptibility to lung cancer in smokers.

Authors:  Hiroshi Kumimoto; Nobuyuki Hamajima; Yoshio Nishimoto; Keitaro Matsuo; Masayuki Shinoda; Shunzo Hatooka; Kanji Ishizaki
Journal:  Jpn J Cancer Res       Date:  2002-01

2.  The insertion/deletion variation in the alpha2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes.

Authors:  Amir Snapir; Mika Scheinin; Leif C Groop; Marju Orho-Melander
Journal:  Cardiovasc Diabetol       Date:  2003-11-24       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.